---
title: "RBC Capital Sticks to Their Buy Rating for Design Therapeutics (DSGN)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295052183.md"
description: "RBC Capital analyst Leonid Timashev maintained a Buy rating on Design Therapeutics (DSGN) with a $20 price target. The stock closed at $12.76. Craig-Hallum also issued a Buy rating with a $22 target. Analyst consensus remains Strong Buy, with an average price target of $24.71, implying significant upside potential."
datetime: "2026-08-06T01:47:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295052183.md)
  - [en](https://longbridge.com/en/news/295052183.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295052183.md)
generator: "portal-rs"
---

# RBC Capital Sticks to Their Buy Rating for Design Therapeutics (DSGN)

RBC Capital analyst Leonid Timashev maintained a Buy rating on Design Therapeutics on August 3 and set a price target of $20.00. The company’s shares closed yesterday at $12.76.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Timashev covers the Healthcare sector, focusing on stocks such as Insmed, Alkermes, and ADC Therapeutics. According to TipRanks, Timashev has an average return of 24.0% and a 60.25% success rate on recommended stocks. 

Design Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $24.71, which is a 93.65% upside from current levels. In a report released on August 4, Craig-Hallum also maintained a Buy rating on the stock with a $22.00 price target.

### Related Stocks

- [DSGN.US](https://longbridge.com/en/quote/DSGN.US.md)
- [RY.US](https://longbridge.com/en/quote/RY.US.md)
- [INSM.US](https://longbridge.com/en/quote/INSM.US.md)
- [ALKS.US](https://longbridge.com/en/quote/ALKS.US.md)
- [ADCT.US](https://longbridge.com/en/quote/ADCT.US.md)

## Related News & Research

- [Design Therapeutics management joins Cantor Fitzgerald Global Healthcare Conference fireside chat](https://longbridge.com/en/news/297782411.md)
- [Alliance Global Partners Sticks to Their Buy Rating for Pelthos Therapeutics (PTHS)](https://longbridge.com/en/news/297544479.md)
- [TransDigm: Buy Rating Reiterated as Strong Results and Aftermarket Strength Support Unchanged $1,615 Price Target](https://longbridge.com/en/news/297850511.md)
- [Attovia Therapeutics, Inc.'s (NASDAQ:ATTO) Quiet Period To End  on September 14th](https://longbridge.com/en/news/298168859.md)
- [Attovia Therapeutics, Inc. (ATTO) Initiated with a Buy at RBC Capital](https://longbridge.com/en/news/297470988.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**